IL6 and COVID-19: One retrospective case series study explored SAR in subcutaneous administration in severe and critical COVID-19 (18), suggesting a clinical benefit through early intervention before high levels of surrogate hyperinflammatory markers such as CRP or IL-6 become irresponsive.